Lucy S. Hodge

Clinical Profile and Neurological Outcomes of Pediatric Patients Supported on Venoarterial Extracorporeal Mechanical Oxygenation in a Cardiorespiratory Pediatric Intensive Care Unit: A Single-Center Study

Swathy Subhash, Naila Ismayilova, Thomas Semple, Andreas Hoschtitzky et autres

Extracorporeal membrane oxygenation (ECMO) has become a standard therapy in extremely sick patients for various indications. This rising use of ECMO warrants careful consideration of its neurological effects. Our single-center retrospective study, conducted between January 2016 and December 2022, on children ≤16 …

gb (code pays fourni par la source)

POS1334 ACHIEVEMENT OF PROTEINURIA TARGETS =0.4 g/g IN LUPUS NEPHRITIS: A POST HOC ANALYSIS OF THE AURORA 1 STUDY OF VOCLOSPORIN

Maria Dall’Era, Brad H. Rovin, Salem Almaani, Lucy S. Hodge et autres

Background: Early proteinuria reduction following treatment initiation is associated with improved long-term kidney survival and overall mortality in lupus nephritis (LN) [1, 2]. Treatment guidelines are based upon achieving urine protein creatinine (UPCR) targets, with UPCR <0.5-0.7 g/g after 12 months often …

us, ca (code pays fourni par la source)

ATTAINMENT OF ULTRA-LOW LEVELS OF UPCR IN THE AURORA 1 STUDY ASSOCIATED WITH ALTERATIONS IN THE CIRCULATING LIPIDOME

Farsad Afshinnia, Subramaniam Pennathur, Michelle Zubrycki, Linda M. Rehaume et autres

PV122 / #252 Poster Topic: AS15 - Lupus Nephritis-Clinical Background/Purpose Lupus nephritis (LN) is an independent risk factor for cardiovascular disease (CVD) and is associated with a nearly 5-fold greater risk of cardiovascular mortality compared to non-renal systemic lupus erythematosus. In the …

us, ca (code pays fourni par la source)

Comparison of a voclosporin-based triple immunosuppressive therapy to high-dose glucocorticoid-based immunosuppressive therapy: a propensity analysis of the AURA-LV and AURORA 1 studies and ALMS

Maria Dall’Era, Kenneth Kalunian, Neil Solomons, Lucy S. Hodge et autres

INTRODUCTION: High-dose glucocorticoid (GC)-based dual immunosuppressive treatment regimens are still frequently used in active lupus nephritis (LN) despite their known association with dose-dependent toxicities and incomplete efficacy. We hypothesised that the addition of voclosporin to low-dose GCs and mycophenolate mofetil (MMF) would …

us, ca (code pays fourni par la source)

Disease Targeting Properties of Voclosporin in Kidney Transplant and Lupus Nephritis Patients

Simon Zhou, Linda M. Rehaume, Ernie Yap, Henry Leher et autres

Background: Voclosporin (VCS), a second generation calcineurin inhibitor, is approved in the United States and Europe for the treatment lupus nephritis (LN) in combination with background immunosuppressive therapy. VCS does not require therapeutic drug monitoring, and is associated with improved glucose, lipid …

ca (code pays fourni par la source)

Enlight-LN Registry: Baseline Demographics and Clinical Characteristics of an Initial Cohort of Patients Treated with Voclosporin for Lupus Nephritis in the United States

Niloofar Nobakht, Laura Geraldino‐Pardilla, Leanna Wise, Mohammad Kamgar et autres

Background: Voclosporin is approved for adults with active lupus nephritis (LN). In the AURORA 1 and AURORA 2 studies, adding voclosporin to MMF and low-dose glucocorticoids led to significantly earlier and greater reductions in proteinuria while maintaining stable eGFR for up to …

us, ca (code pays fourni par la source)

Immunologic Changes over Time in Repeat Kidney Biopsies from the AURORA Studies of Voclosporin in Lupus Nephritis

Samir V. Parikh, Maddalena M. Bolognesi, Ivana Grbeša, Brad H. Rovin et autres

Background: The AURORA 1 and 2 studies investigated the use of voclosporin (VCS) plus standard-of-care (SOC) for the treatment of lupus nephritis (LN). All patients underwent a kidney biopsy for enrollment (Bx1), and a subset of patients elected to undergo a second …

us, it, no, ca (code pays fourni par la source)

OP0059 VOCLOSPORIN-BASED, TRIPLE-IMMUNOSUPPRESSIVE REGIMEN VERSUS HIGH-DOSE GLUCOCORTICOID AND MYCOPHENOLATE MOFETIL-BASED THERAPY FOR LUPUS NEPHRITIS: A PROPENSITY ANALYSIS OF THE ALMS, AURA-LV AND AURORA 1 STUDIES

A. Askanase, Kenneth Kalunian, Maria Dall’Era, N. Solomons et autres

#468 Voclosporin-based, triple-immunosuppressive therapy vs high-dose glucocorticoid-based dual-immunotherapy for lupus nephritis: a propensity analysis

Ernie Yap, Anca Askanase, Kenneth Kalunian, Maria Dall’Era et autres

Abstract Background and Aims Voclosporin is a second generation calcineurin inhibitor (CNI) approved for the treatment of adults with active lupus nephritis (LN) in combination with immunosuppressive therapy. An integrated analysis of the Phase 2 AURA-LV and Phase 3 AURORA 1 studies …

ca, us (code pays fourni par la source)

1007 Voclosporin for lupus nephritis: assessment of long-term safety and efficacy including renal outcome over three years of treatment in the phase 3 AURORA 1 and AURORA 2 studies

Samir V. Parikh, Cristina Arriens, Lucy S. Hodge, Christopher M. Mela et autres

Background In AURORA 1, adding voclosporin to mycophenolate mofetil (MMF) and low-dose steroids led to signficant reductions in proteinuria at one year in patients with lupus nephritis (LN). We report on the recently completed AURORA 2 study evaluating voclosporin compared to placebo …

us, ca (code pays fourni par la source)

P87 Comparison of a voclosporin-based, triple immunotherapy regimen to high-dose glucocorticoid-based immunosuppressive therapy: a propensity analysis of the AURA-LV plus AURORA 1 studies and ALMS

Maria Dall’Era, Kenneth Kalunian, Anca Askanase, Neil Solomons et autres

Objective Early reduction in proteinuria after initial treatment has been associated with improved long-term kidney outcomes in lupus nephritis (LN). The addition of voclosporin, a second generation calcineurin inhibitor, to MMF and low-dose glucocorticoids (GC)s led to greater reductions in proteinuria compared …

us, ca (code pays fourni par la source)

Efficacy of Voclosporin in Proliferative Lupus Nephritis with High Levels of Proteinuria

Hanni Menn‐Josephy, Lucy S. Hodge, Vanessa Birardi, Henry Leher

BACKGROUND: In a phase 3 study of adults with active lupus nephritis, addition of voclosporin to mycophenolate mofetil (MMF) and low-dose glucocorticoids led to significant improvements in the proportion of participants achieving complete and partial renal response as well as sustained reduction …

us, ca (code pays fourni par la source)